TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05913050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic resistance exercise
Description: Therapeutic exercise program based on individualized progressive resistance exercises performed during 3 months at home, with a frequency of 1-3 sessions per week at the hospital.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education applied during all the therapeutic process, focusing on diverting the patient's attention away from the structural lesion, explaining the relationship between pain/disability and tissue injury, explaining the meaning of pain during exercises, and explaining the objectives of the implemented treatments.
Study: NCT05143749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video tutorial
Description: get video tutorial
Study: NCT06501638

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take placebo for intervention First week, half the tablet, p.o., bid. Second to Sixth week, one tablet, p.o., bid
Study: NCT06459284

Intervention type: OTHER
Intervention: retrospective data analysis
Description: Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling

Intervention type: OTHER
Intervention: retrospective data analysis
Description: Surgical video-documentation including continous iOCT will ne reviewed for Instrument tissue interactions at the grasp site of the starting point of Membrane peeling
Study: NCT05969899

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFIRI+Bevacizumab
Description: irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
Study: NCT05421832

Intervention type: DEVICE
Intervention: Digital Speech Application
Description: A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.

Intervention type: DEVICE
Intervention: Digital Speech Application
Description: A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.

Intervention type: DEVICE
Intervention: Digital Speech Application
Description: A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.

Intervention type: DEVICE
Intervention: Digital Speech Application
Description: A custom smartphone-based speech assessment tool to extract multiple hypothesis-driven acoustic features from patient speech in a real-life environment.
Study: NCT05211232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy
Study: NCT06263907

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate gangalion block
Description: The efficacy of Preoperative ipsilateral stellate gangalion block on the occurrence of postmastectomy depression and pain compared with no block
Study: NCT05028348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor will be given as an oral dose 40 mg (2 20 mg tablets) QW on Days 1, 8, 15, and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab will be given IV 10 mg/kg on Days 1, 8, 15, and 22 of cycle 1 and 2 then 20 mg/kg on Day 1 of cycles ≥3 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide will be given as an oral 4 mg dose QD on Days 1 to 21 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Oral
Description: Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: Dexamethasone will be given as an oral 40 mg dose QW on Days 1, 8, 15, and 22 of each 28-day cycle. Preferred dosing of dexamethasone is 40 mg QW for patients who are ≤75 years of age (20 mg QW for \>75-year-old patients at the Investigator's discretion) before QW dosing of selinexor, however, it may be divided over 2 days at the Investigator's discretion.
Study: NCT04244981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate, Human
Description: A 4-factor prothrombin complex concentrate (Confidex®, CSL Behring, Marburg, Germany), containing a defined concentration of the four vitamin K-dependent clotting factors (II, VII, IX and X) and the thrombo-inhibitor proteins C and S. Each vial of Confidex® contains a relatively high concentration of coagulation factor II (20-48 IU/mL), factor VII (10-25 IU/mL), factor IX (20-31 IU/mL), factor X (22-60 IU/mL), proteins C (15-45 IU/mL), proteins S (13-38 IU/mL), Heparin (0.5 IU/mL), and antithrombin (0.6 IU/mL). When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 8～15 IU/kg PCC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fresh Frozen Plasma
Description: When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
Study: NCT05572606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Description: Seven pre-recorded hypnotherapy sessions delivered over the course of twelve weeks via the patient's own electronic device such as a smartphone, tablet, or laptop. The length of the audio-recorded treatment sessions is expected to be approximately 40 minutes on average.
Study: NCT04812028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.
Study: NCT06327373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Supplemental oxygen by oxygen concentrator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Supplemental oxygen by oxygen concentrator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room air
Description: Room air without oxygen concentrator
Study: NCT03631771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Iohexol administered intravascularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Iodixanol administered intravascularly
Study: NCT04729114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRL-02 injection
Description: abiraterone decanoate for intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Oral capsule
Study: NCT05243108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary nucleotides
Description: 1.2 g/d NTs (5 '-AMP, 5' -CMP, 5 '-GMPNa2, 5' -UMPNa2) ;

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT04928001

Intervention type: OTHER
Group type: OTHER
Intervention: internet based iCBT program, Youth Thrive
Description: iCBT program is a skills program which teaches assertive communication, constructive thinking and rewarding activities
Study: NCT05254678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: general exercise
Description: A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general exercise
Description: A 10-week integrated physiotherapy and general exercise intervention compared to a general exercise intervention alone.
Study: NCT05688436

Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Alemtuzumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Fingolimod
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Glatiramer acetate
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Interferon beta
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Natalizumab
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Ocrelizumab
Description: Administered as specified in the treatment arm.
Study: NCT05036018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: minimalist approach
Description: Isolated local anesthesia. Central venous lines, additional arterial lines for blood pressure monitoring, and urinary catheters will be avoided. Insertion of temporary pacemakers is optional and should be avoided whenever possible, and peri-procedural pacing can then be performed on the left ventricular wire. Presence of an anesthesiologist is optional. Patients will be directly transferred to the cardiology ward after the procedure, which can be postponed in case of complications.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve Evolut Pro and Pro+
Description: The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoreValve Evolut Pro and Pro+
Description: The Evolut Pro or Pro+ valve is positioned in a controlled manner either without pacing or under 'slow-rapid' pacing with allowance for limited repositioning and is anchored to the annulus and ascending aorta.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Sedation should be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -2 according to local standard of care.The use of EEG monitoring (i.e. BIS, Sedline) can be applied. Continuous CO2-monitoring via face mask should be established during sedation. All patients will receive supplemental oxygen by face mask to maintain an oxygen saturation of approximately 95%. Presence of an anesthesiologist is obligatory. The use of central venous catheters, additional arterial lines for blood pressure monitoring, and urinary catheters can be implemented according to local institutional standards.
Study: NCT06263491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Given by PO
Study: NCT06349590

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fiber/low-fat meals
Description: Meals with Low fat/High fiber
Study: NCT05688436

Intervention type: BIOLOGICAL
Intervention: Ofatumumab
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Ozanimod
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Peginterferon beta-1a
Description: Administered as specified in the treatment arm.
Study: NCT05376982

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment
Description: Using Neurodevelopmental Treatment Method
Study: NCT05159219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Anti-inflammatory

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inert ingredients
Study: NCT06364423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HuCD19 ( Anti-CD19)CAR T cells
Description: 1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous HuCD19 ( Anti-CD19)CAR T cells
Description: 1.0x10\^6 CAR+T-cells - 12x10\^6 CAR+ T cells/kg (weight based dosing per cohort) infused on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 IV infusion over 30 minutes on days -5, -4 and -3
Study: NCT05376982

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Body weight supported treadmill training along with conventional therapy
Description: Using Body weight supported treadmill training along with conventional therapy Method
Study: NCT03631771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopromide
Description: Iopromide administered intravascularly
Study: NCT05803109

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AVIVA-PURE-CocoPull-Organic-made in USA
Description: virgin cold pressed coconut oil with Peppermint essential oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AVIVA-PURE-CocoPull-Organic-made in USA
Description: virgin cold pressed coconut oil with Peppermint essential oil
Study: NCT05081804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Preoperative Drink
Description: Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Preoperative Drink
Description: Patients randomized to the intervention will drink the preoperative drink two hours prior to surgery
Study: NCT05688436

Intervention type: DRUG
Intervention: Ponesimod
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Siponimod
Description: Administered as specified in the treatment arm.
Study: NCT05757570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povetacicept
Description: Administered by subcutaneous injection every 4 weeks
Study: NCT03631771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ioversol
Description: Ioversol administered intravascularly
Study: NCT06098677

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carotenoids supplementation
Description: Daily oral supplementation of a soft gel capsule containing 10mg lutein (L), 10mg meso-zeaxanthin (MZ) and 2mg zeaxanthin (Z).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral supplementation of a soft gel capsule containing only placebo oil
Study: NCT06285604

Intervention type: PROCEDURE
Intervention: Blood transfusion
Description: Transfusion of designated red blood cell products to anemic neonates.
Study: NCT04627090

Intervention type: OTHER
Intervention: Data collection
Description: Diagnostic and therapeutic data of adult patients with LCH, collected from clinical and laboratory evaluations, carried out during clinical practice.
Study: NCT06364423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
Study: NCT06125197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TILT-123
Description: Tumor necrosis factor alpha (TNFalpha) and Interleukin-2 (IL-2) coding oncolytic adenovirus TILT-123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KEYTRUDA®
Description: pembrolizumab, a monoclonal antibody binding PD-1
Study: NCT06457971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic Ventral Hernia Repair
Description: The AnovoTM Surgical System is an endoscopic instrument control system that is intended to assist in the accurate control of the Instrument ARMS with graspers and electrosurgery devices for endoscopic manipulation of tissue including grasping, blunt dissection, approximation, and electrosurgery, during single site, laparoscopic surgical procedures. The AnovoTM System's articulated robotic arms allow the surgeon to access and reach different structures in the pelvic and abdominal cavity. Closing the fascial defect robotically is easier from a technical standpoint than attempting it with classical laparoscopic instruments
Study: NCT06514677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Carbon Tip
Description: Using Ultrasonic Carbon Tip for Non-surgical Peri-implantitis Treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Curette
Description: Using Titanium Curettes for for Non-surgical Peri-implantitis Treatment
Study: NCT05766319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings ScanWatch
Description: Withings ScanWatch, from which the following features will be used:~* Measurement of peripheral oxygen saturation (%)~* Automatic recording of heart rate (beats/min)~* Automatic recording of activity (step count) (numbers/day)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings BPM Connect
Description: Withings BPM connect, from which the following feature will be used:~o Measurement of non invasive bloodpressure (mmHg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Withings Body
Description: Withings Body (Scale), from which the following feature will be used:~o Measurement of body weight (kg)
Study: NCT04751799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset before colposcopy
Description: Patients wear a virtual headset presenting 360° 3D views of relaxing environments
Study: NCT06285604

Intervention type: PROCEDURE
Intervention: Blood transfusion
Description: Transfusion of designated red blood cell products to anemic neonates.

Intervention type: PROCEDURE
Intervention: Blood transfusion
Description: Transfusion of designated red blood cell products to anemic neonates.
Study: NCT05103553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Clinic
Description: Follow-up in outpatient clinic
Study: NCT05313269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ISAFE technique for adductor canal catheter insertion
Description: Adductor canal block catheter tip located in the fascial plane between sartorious muscle and femoral artery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique for adductor canal catheter insertion
Description: Adductor canal block catheter tip located lateral to the femoral artery.